首页> 外文期刊>Advanced Pharmaceutical Bulletin >Bio Pharmaceutics Classification System (BCS) Class IV Drug Nanoparticles: Quantum Leap to Improve Their Therapeutic Index
【24h】

Bio Pharmaceutics Classification System (BCS) Class IV Drug Nanoparticles: Quantum Leap to Improve Their Therapeutic Index

机译:生物药物分类系统(BCS)IV类药物纳米颗粒:改善其治疗指数的量子飞跃

获取原文
           

摘要

Purpose: Biopharmaceutics classification system (BCS) class IV compounds, exhibits least oral bioavailability, low solubility and intestinal permeability among all pharmaceutical classes of drugs. Thus, these drugs need more compatible and efficient delivery system. Since, their solubility in various medium, remains a limitation so, polymeric nano coacervates based drug loading with modified approach for them may prove to be a solution ahead. Therefore, in present study Chitosan is opted for encapsulating the BCS class IV drug (Hydrochlorothiazide) to attain better stability, enhanced permeability and lower toxicity. Methods: For this study, Hydrochlorothiazide (HCTZ) was opted for formulating chitosan based nano-coacervate system. Results: Optimized HCTZ nanocoacervates exhibited the average particle size of 91.39 ± 0.75 nm with Poly-dispersity index score of 0.159 ± 0.01, indicating homogeneity of colloidal solution. Zeta potential and encapsulation efficiency of HCTZ nanocoacervates were recorded as -18.9 ± 0.8 mV and 76.69 ± 0.82 % respectively. Further, from TEM and SEM evaluation the average particle size for the same were found in conformity (35-50 nm), with almost spherical morphology. Also, the EDX (Electron Dispersive X-ray) spectrometry and FT – IR analysis of optimized formulation indicated the balanced chemical composition and interaction between the polymeric molecules. The HCTZ nano coacervates showed the linear diffusion profile through the dialysis membrane. Conclusion: We can conclude from the present study that the optimized HCTZ nano coacervates may prove to be a suitable potential option for effective delivery of BCS class IV drugs.
机译:目的:生物制药分类系统(BCS)IV类化合物,在所有药物类别的药物中均表现出最低的口服生物利用度,低溶解度和肠道通透性。因此,这些药物需要更兼容和更有效的递送系统。由于它们在各种介质中的溶解度仍然是一个限制,因此,基于聚合物纳米凝聚层的载药方法经过改进的药物可能被证明是未来的解决方案。因此,在本研究中,壳聚糖选择包封BCS IV类药物(氢氯噻嗪)以获得更好的稳定性,增强的通透性和更低的毒性。方法:本研究选择氢氯噻嗪(HCTZ)配制基于壳聚糖的纳米凝聚层体系。结果:优化的HCTZ纳米凝聚层的平均粒径为91.39±0.75 nm,多分散指数得分为0.159±0.01,表明胶体溶液的均质性。 HCTZ纳米凝聚层的Zeta电位和包封效率分别为-18.9±0.8 mV和76.69±0.82%。此外,通过TEM和SEM评价,发现其平均粒径大致为球形(35-50nm)。同样,EDX(电子色散X射线)光谱法和优化配方的FT-IR分析表明,化学成分之间的平衡以及聚合物分子之间的相互作用。 HCTZ纳米凝聚层显示出穿过透析膜的线性扩散曲线。结论:我们可以从本研究中得出结论,优化的HCTZ纳米凝聚层可能被证明是有效递送BCS IV类药物的合适潜在选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号